Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: Results of a clonal analysis

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 1, 2006, Pages 60-64

  Lu, Jing ^a,b   Deeks, Steven G ^c,d   Hoh, Rebecca ^c,d   Beatty, George ^c,d   Kuritzkes, Benjamin A ^a,b   Martin, Jeffrey N ^c   Kuritzkes, Daniel R ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Drug resistance; Enfuvirtide; Fusion inhibitors; HIV 1

Indexed keywords

ENFUVIRTIDE;

ARTICLE; CLINICAL TRIAL; CODON; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOLECULAR CLONING; MOLECULAR DYNAMICS; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE; VIROLOGY; VIRUS RESISTANCE;

AMINO ACID SEQUENCE; CLONING, MOLECULAR; DNA PRIMERS; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33748115445     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000234083.34161.55     Document Type: Article

References (21)

1. Chan DC, Fass D, Berger JM, et al. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997;89:263-273.
2. Wild CT, Shugars DC, Greenwell TK, et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A. 1994;91:9770-9774.
3. Kilby JM, Hopkins S, Venetta T, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med. 1998;4:1302-1307.
4. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-2195.
5. Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175-2185.
6. Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol. 1998;72:986-993.
7. Sista PR, Melby T, Davison D, et al. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates. AIDS. 2004;18:1787-1794.
8. Xu L, Pozniak A, Wildfire A, et al. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41. Antimicrob Agents Chemother. 2005;49:1113-1119.
9. Mink M, Mosier SM, Janumpalli S, et al. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol. 2005;79:12447-12454.
10. Marcelin AG, Reynes J, Yerly S, et al. Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20. AIDS. 2004;18:1340-1342.
11. Lu J, Sista P, Giguel F, et al. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20). J Virol. 2004;78:4628-4637.
12. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534-1543.
13. Felsenstein J. PHYLIP: Phylogeny Inference Package, Version 3.5c. Seattle, WA: University of Washington; 1993.
14. Page RDM. Treeview: an application to display phylogenetic trees on personal computers. Comput Appl Biosci. 1996;12:357-358.
15. Swanstrom R, Bosch RJ, Katzenstein D, et al. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis. 2004;190:886-893.
16. Beatty G, Hunt P, Smith A, et al. A randomized pilot study comparing combination therapy plus enfuvirtide versus a treatment interruption followed by combination therapy plus enfuvirtide. Antivir Ther. 2006;11:315-319.
17. Poveda E, Rodes B, Lebel-Binay S, et al. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. J Clin Virol. 2005;34:295-301.
18. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
19. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol. 1994;68:1660-1666.
20. Valdez H, McCallister S, Kohlbrenner V, et al. Tipranavir/ritonavir (TPV/r) 500 mg/200 mg bid drives week 24 viral load (VL) below 400 copies/mL when combined with a second active drug (T-20) in protease inhibitor experienced HIV+ patients. In: Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment, July 24-27, 2005; Rio de Janeiro, Brazil. Abstract We.Oa.0205.
21. Wilkin T, Haubrich R, Steinhart CR, et al. TMC114/r superior to standard of care in 3-class-experienced patients: 24-wks primary analysis of the power 2 study (C202). In: Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, December 16-19, 2005; Washington, DC. Abstract H-413.